Stams T, Chen Y, Boriack-Sjodin P A, Hurt J D, Liao J, May J A, Dean T, Laipis P, Silverman D N, Christianson D W
Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia 19104-6323, USA.
Protein Sci. 1998 Mar;7(3):556-63. doi: 10.1002/pro.5560070303.
Carbonic anhydrase IV (CAIV) is a membrane-associated enzyme anchored to plasma membrane surfaces by a phosphatidylinositol glycan linkage. We have determined the 2.8-angstroms resolution crystal structure of a truncated, soluble form of recombinant murine CAIV. We have also determined the structure of its complex with a drug used for glaucoma therapy, the sulfonamide inhibitor brinzolamide (Azopt). The overall structure of murine CAIV is generally similar to that of human CAIV; however, some local structural differences are found in the active site resulting from amino acid sequence differences in the "130's segment" and the residue-63 loop (these may affect the nearby catalytic proton shuttle, His-64). Similar to human CAIV, the C-terminus of murine CAIV is surrounded by a substantial electropositive surface potential that may stabilize the interaction with the phospholipid membrane. Binding interactions observed for brinzolamide rationalize the generally weaker affinity of inhibitors used in glaucoma therapy toward CAIV compared with CAII.
碳酸酐酶IV(CAIV)是一种通过磷脂酰肌醇聚糖连接锚定在质膜表面的膜相关酶。我们已经确定了重组鼠CAIV截短的可溶性形式的2.8埃分辨率晶体结构。我们还确定了它与用于青光眼治疗的药物——磺胺类抑制剂布林佐胺(Azopt)的复合物结构。鼠CAIV的整体结构与人类CAIV的结构总体相似;然而,由于“130段”和63位残基环中的氨基酸序列差异,在活性位点发现了一些局部结构差异(这些差异可能影响附近的催化质子穿梭体His-64)。与人类CAIV相似,鼠CAIV的C末端被大量的正电表面电位包围,这可能稳定与磷脂膜的相互作用。观察到的布林佐胺结合相互作用解释了与CAII相比,青光眼治疗中使用的抑制剂对CAIV的亲和力通常较弱的原因。